AbbVie (ABBV) AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

AbbVie (NYSE: ABBV) FY 2026 Other Release

Newsdesk: